Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Milrinone lactate
Drug ID BADD_D01468
Description Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart failure is underpinned by numerous physiological changes, including alteration in β-adrenergic signalling and cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and cardiac output.[A228323] Milrinone is a second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of [amrinone].[A228333] As a PDE-III inhibitor, milrinone results in increased cAMP levels and improves cardiac function and peripheral vasodilation in acute decongested heart failure.[A228338, A11759, A228323, A228333, A228348, L31483] Milrinone was originally synthesized at the Sterling Winthrop Research Institute in the 1980s.[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]
Indications and Usage Milrinone is indicated for the short-term (48 hours or less) treatment of patients with acute decompensated heart failure. Milrinone administration should occur together with close monitoring using appropriate electrocardiographic equipment and should occur in a facility equipped for the immediate treatment of potential cardiac events, including ventricular arrhythmias.[L31483]
Marketing Status approved
ATC Code C01CE02
DrugBank ID DB00235
KEGG ID D02085
MeSH ID D020105
PubChem ID 172293
TTD Drug ID D0Y9ZE
NDC Product Code 0338-6010; 65145-121; 72485-503; 63323-617; 65145-122; 0409-0212; 70069-807; 72485-502; 42677-313; 65145-120; 72485-501; 0143-9326; 0143-9374; 68083-410; 0143-9708; 71288-200; 25021-313; 0143-9373; 0143-9709; 0143-9710; 42677-314; 68083-411; 70069-808; 70069-809; 0338-6011
UNII 9K8XR81MO8
Synonyms Milrinone | Win-47203 | Win 47203 | Win47203 | Primacor | Corotrope | Corotrop | Milrinone Lactate | Lactate, Milrinone
Chemical Information
Molecular Formula C15H15N3O4
CAS Registry Number 100286-97-3
SMILES CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2.CC(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Arrhythmia supraventricular02.03.03.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Headache17.14.01.001--
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Liver function test abnormal13.03.04.030--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Thrombocytopenia01.08.01.002--Not Available
Torsade de pointes02.03.04.005--Not Available
Tremor17.01.06.002--
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
The 1th Page    1    Total 1 Pages